Use of flavone derivatives for induction of β-lactam-sensitivity of MRSA
AssigneeAlps Pharmaceutical Ind. Co., Ltd.
InventorsTomihiko Higuchi, Yoichi Sato, Shoji Murasugi
Life of this patent
Estimating the term…
Abstract
A novel screening system for detecting a non-antibiotic compound having β-lactam-sensitivity-inducing activity comprising a non-antibiotic compound and a β-lactam antibiotic two times serially diluted series and a pharmaceutical composition having anti-MRSA activity comprising a flavone derivative and a β-lactam antibiotic.
Claims15
A method for increasing antibacterial activity of a β-lactam antibiotic against methicillin-resistant Staphylococcus aureus which comprises adding a flavone derivative selected from the group consisting of flavone, apigenin, luteohn, eriodictyol, phloretin and (+)-taxifoline to the β-lactam antibiotic in an amount effective to increase antibacterial activity of the β-lactam antibiotic against the methicillin-resistant Staphylococcus aureus.
A pharmaceutical composition comprising a β-lactam antibiotic and at least one flavone derivative selected from the group consisting of flavone, apigenin, luteolin, eriodictyol, phloretin and (+)-taxifoline, said flavone derivative being present in an amount effective to increase antibacterial activity of the β-lactam antibiotic against methicillin-resistant Staphylococcus aureus.
A method for treating an infectious disease of which the source of infection is methicillin-resistant Staphylococcus aureus which comprises administering a β-lactam antibiotic and a flavone derivative selected from the group consisting of flavone, apigenin, luteolin, eriodictyol phloretin and (+)-taxifoline, said flavone derivative being administered in an amount to increase antibacterial activity of the β-lactam antibiotic against the methicillin-resistant Staphylococcus aureus.
Dependencies are inferred from the claim text.